Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics elects seven directors; withdraws CIRM grant application

Neutral Impact 2 of 5 shareholder Written later

At its June 10, 2026 annual meeting, shareholders elected seven directors, ratified Baker Tilly US, LLP as auditor for 2026, and approved the executive pay package on an advisory basis. Separately, on June 9, 2026, the company withdrew its application for a California Institute for Regenerative Medicine (CIRM) grant to support OPC1 development in spinal cord injury after receiving CIRM comments. The company states the withdrawal does not affect the ongoing DOSED study.

Key points

  • All seven board nominees were elected to serve until the 2027 annual meeting; Michael H. Mulroy received 90,383,337 votes for and 1,201,448 withheld.
  • Baker Tilly US, LLP was ratified for fiscal 2026 with 163,825,928 votes for, 659,670 against and 1,017,041 abstentions.
  • The advisory say-on-pay vote passed with 88,328,168 votes for, 2,600,932 against and 655,685 abstentions.
  • On June 9, 2026, the company withdrew its CIRM Clinical Trial (CLIN2) grant application, which it had filed in January 2026.

The filing

CompanyLineage Cell Therapeutics, Inc. (LCTX)
Form8-K, current report
Filed with the SECJun 12, 2026, 4:32 PM ET
Accession number0001193125-26-269557

Items reported: 5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:28 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.